Reducing mortality in sepsis: New directions

Critical Care

Volumn 6, Issue SUPPL. 3, 2002, Pages

  Vincent, Jean Louis ^a   Abraham, Edward ^b   Annane, Djillali ^c   Bernard, Gordon ^d   Rivers, Emanuel ^e   Van den Berghe, Greet ^f  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITY OF COLORADO   (United States)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Intensive care unit; Intervention; Mortality; Sepsis

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; DROTRECOGIN; GLUCOSE; HYPERTENSIVE FACTOR; INOTROPIC AGENT; INSULIN; OXYGEN; PLACEBO; STEROID;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL STUDY; CONTINUING EDUCATION; CORTICOTROPIN TEST; DISEASE COURSE; DOSE RESPONSE; ERYTHROCYTE TRANSFUSION; FLUID THERAPY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INTENSIVE CARE UNIT; LUNG INJURY; MEDICAL DECISION MAKING; MEDICAL EXPERT; MORTALITY; MOTIVATION; MYOCARDIAL DISEASE; OXYGEN CONSUMPTION; OXYGEN TRANSPORT; PATIENT CARE; PATIENT SELECTION; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; SYMPTOM; THROMBOCYTOPENIA; TIDAL VOLUME; TREATMENT OUTCOME;

ANIMALS; ANTI-INFECTIVE AGENTS; CRITICAL CARE; HUMANS; INSULIN; INTENSIVE CARE UNITS; PROTEIN C; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; RESPIRATION, ARTIFICIAL; SEPSIS;

EID: 0036972302     PISSN: 13648535     EISSN: None     Source Type: Journal    
DOI: 10.1186/cc1860     Document Type: Review

References (49)

1. Hoyert DL, Arias E, Smith BL, Murphy SL, Kochanek KD: National Vital Statistics Reports [serial online], 21 September 2001 [http://www.cdc.gov/nchs/data/nvsr/nvsr49/nvsr49_08.pdf], accessed 1 October 2002.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
3. The task force on the management of acute myocardial infarction of the European Society of Cardiology. Eur Heart J 1996, 17:43-63.
4. Angus DC, Wax RS: Epidemiology of sepsis: an update. Crit Care Med 2001, 29:S109-S116.
5. Balk RA: Severe sepsis and septic shock. Definitions, epidemiology, and clinical manifestations. Crit Care Clin 2000, 16:179-192.
6. Bone RC: Gram-negative sepsis: a dilemma of modern medicine. Clin Microbiol Rev 1993, 6:57-68.
7. Vincent JL: Sepsis definitions. Lancet Infect Dis 2002, 2:135.
8. Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med 1998, 26:1793-1800.
9. Milberg JA, Davis DR, Steinberg KP, Hudson LD: Improved survival of patients with Acute Respiratory Distress Syndrome (ARDS): 1983-1993 [Concepts in Emergency and Critical Care]. JAMA 1995, 273:306-309.
10. Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN: The HA-1A Sepsis Study Group. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1991, 324:429-436.
11. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AI: Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982, 307:1225-1230.
12. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R: The TNFα MAb Sepsis Study Group: monoclonal antibody to human tumor necrosis factor alpha (TNFα MAb): efficacy and safety in patients with the sepsis syndrome. JAMA 1995, 273:934-941.
13. Abraham E, Reynaert M, Lew D, Pingleton S, Butler T, Dugernier T, Margolis B, Kudsk K, Zimmerli W, Anderson P, Reynaert M, Lew D, Lesslauer W, Passe S, Cooper P, Burdeska A, Modi M, Leighton A, Salgo M, Van der Auwera P, Lenercept Study Group: Lenercept (p55-Tumor Necrosis Factor Receptor Fusion Protein, Ro 45-2081, Tenefuse) patients with severe sepsis or early septic shock. A randomized double-blind placebo-controlled multicenter phase III trial with 1342 patients. Crit Care Med 2001, 29:503-510.
14. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr, Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
15. Wheeler AP, Bernard GR: Current concepts: treating patients with severe sepsis. N Engl J Med 1999, 340:207-214.
16. Vincent JL: Need for intensivists in intensive care units [commentary]. Lancet 2000, 356:695-696.
17. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988, 2:349-360.
18. Tremblay L, Valenza F, Ribeiro SP, Li J, Slutsky AS: Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. J Clin Invest 1997, 99:944-952.
19. Ranieri VM, Suter PM, Tortorella C, De Tullio R, Dayer JM, Brienza A, Bruno F, Slutsky AS: Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA 1999, 282:54-61.
20. Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, Kairalla RA, Deheinzelin D, Munoz C, Oliveira R, Takagaki TY, Carvalho CR: Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998, 338:347-354.
21. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000, 342:1301-1308.
22. Martin GS, Bernard GR: Airway and lung in sepsis. Intensive Care Med 2001, 27:S63-S79.
23. Hayes TA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D: Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994, 330:1717-1722.
24. 2 Collaborative Group. N Engl J Med 1995, 333:1025-1032.
25. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Early Goal-Directed Therapy Collaborative Group: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345: 1368-1377.
26. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine: Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Crit Care Med 1999, 27:639-660.
27. Nguyen HB, Rivers EP, Havstad S, Knoblich B, Ressler JA, Muzzin AM, Tomlanovich MC: Critical care in the emergency department: a physiologic assessment and outcome evaluation. Acad Emerg Med 2000, 7:1354-1361.
28. Nelson M, Waldrop RD, Jones J, Randall Z: Critical care provided in an urban emergency department. Am J Emerg Med 1998, 16:56-59.
29. Donnino M, Nguyen B, Rivers E: A hemodynamic comparison of early and late phase severe sepsis and septic shock. Chest 2002, 122:5S.
30. Yan SB, Helterbrand JD, Hartman DL, Wright TJ, Bernard GR: Low levels of protein C are associated with poor outcomes in severe sepsis. Chest 2001, 120:915-922.
31. Hesselvik JF, Malm J, Dahlback B, Blomback M: Protein C, protein S, C4b-binding protein in severe infection and septic shock. Thomb Haemost 1991, 65:126-129.
32. Mesters RM, Helterbrand J, Utterback BG, Yan B, Chao YB, Fernandez JA, Griffin JH, Hartman DL: Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 2000, 28:2209-2216.
33. Leclerc F, Hazelzet J, Jude B, Hofhuis W, Hue V, Martinot A, Van der Voort E: Protein C and S deficiency in severe infectious purpura of children: a collaborative study of 40 cases. Intensive Care Med 1992, 18:202-205.
34. Powars D, Larsen R, Johnson J, Hulbert T, Sun T, Patch MJ, Francis R, Chan L: Epidemic meningioccemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis 1993, 17:254-261.
35. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987, 79:918-925.
36. Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S, Ferrell G, Chang AC, Laszik Z, Kosanke S, Peer G, Esmon CT: The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000, 95:1680-1686.
37. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, Fisher CJ Jr: Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995, 23:1430-1439.
38. Lefering R, Neugebauer EA: Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995, 23:1294-1303.
39. Annane D, Sébille V, Troché G, Raphael JC, Gajdos P, Bellissant E: A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000, 283:1038-1045.
40. Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K: Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blinded, single-center study. Crit Care Med 1999, 27:723-732.
41. Meduri GU, Tolley EA, Chrousos GP, Stentz F: Prolonged methyl-prednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med 2002, 165:983-991.
42. Beishuizen A, Thijs LG, Vermes I: Patterns of corticosteroid-binding globulin and the free cortisol index during septic shock and multitrauma. Intensive Care Med 2001, 27:1584-1591.
43. Koo DJ, Jackman D, Chaudry IH, Wang P: Adrenal insufficiency during the late stage of polymicrobial sepsis. Crit Care Med 2001, 29:618-622.
44. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998, 26:645-650.
45. Annane D, Sébille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaut P, Bellissant E: Effect of a treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002, 288:862-971.
46. Van den Berghe G, Wouters P, Weekers F, Mohan S, Baxter RC, Veldhuis JD, Bowers CY, Bouillon R: Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 1999, 84:1311-1323.
47. Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Veldhuis JD: A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. J Clin Endocrinol Metab 2000, 85:183-192.
48. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001, 345:1359-1367.
49. Morris AH: Decision support and safety of clinical environments. Qual Saf Health Care 2002, 11:69-75.